Security
Unicycive Therapeutics, Inc. Common Stock · UNCY
UNCYNASDAQCommon stockCurrentCIK 1766140Updated Oct 6, 2026
Name history
Unicycive Therapeutics, Inc. · through Oct 1, 2026
UNCY price & chart
Loading TradingView…
NASDAQ:UNCY on TradingView ↗About the company
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
In the news
ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY ↗
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit ↗
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm ↗
Recent filings
3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01, 9.01
Other Events
Items 8.01
SCHEDULE 13G/A - filed by Vivo Opportunity Fund Holdings, L.P. regarding Unicycive Therapeutics, Inc.
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 49,135,000Source | 31,668,000Source | 14,191,000Source | 2,818,000Source |
| Property, Plant and Equipment, NetUSD | 66,000Source | 75,000Source | 26,000Source | 22,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 29,198,000Source | — | — | 455,000Source |
| Inventory, NetUSD | — | — | — | 2,189,000Source |
| Assets, CurrentUSD | 48,961,000Source | 30,948,000Source | 13,399,000Source | 2,644,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,692,000Source | 4,806,000Source | 3,698,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 108,000Source | 645,000Source | 766,000Source | 152,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 18,938,000Source | 24,237,000Source | 18,000,000Source | 3,284,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 22,000Source | 114,000Source | 35,000Source | 15,000Source |
| Additional Paid in CapitalUSD | 158,001,000Source | 108,587,000Source | 60,697,000Source | 33,516,000Source |
| Retained Earnings (Accumulated Deficit)USD | -127,825,000Source | -101,270,000Source | -64,541,000Source | -33,997,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,000Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | 30,197,000Source | 7,431,000Source | -3,809,000Source | -466,000Source |
| Liabilities and EquityUSD | 49,135,000Source | 31,668,000Source | 14,191,000Source | 2,818,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 18,938,000Source | 24,120,000Source | 17,534,000Source | 3,284,000Source |
| Operating Lease, Liability, CurrentUSD | 117,000Source | 564,000Source | 327,000Source | 155,000Source |
| Accounts Payable, CurrentUSD | 383,000Source | 1,058,000Source | 839,000Source | 892,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 117,000Source | 466,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,523,000Source | 3,562,000Source | 3,234,000Source | 2,237,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 428,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,641,000Source | 2,350,000Source | 1,767,000Source | 1,047,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -31,317,000Source | -28,575,000Source | -18,283,000Source | -15,651,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -12,095,000Source | -72,000Source | -12,000Source | -2,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 24,000Source | 72,000Source | 12,000Source | 2,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 46,468,000Source | 45,088,000Source | 27,541,000Source | -471,000Source |
| Dividends paid | — | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | -16,124,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 29,198,000Source | 26,142,000Source | 9,701,000Source | 455,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 12,000Source | 24,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,641,000Source | 2,350,000Source | 1,767,000Source | 1,047,000Source |
| DepreciationUSD | 34,000Source | 22,000Source | 9,000Source | 7,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | 2,800,000Source | 2,800,000Source | 5,700,000Source | — |
| General and Administrative ExpenseUSD | 20,396,000Source | 12,103,000Source | 8,547,000Source | 6,567,000Source |
| InterestExpenseNonoperatingUSD | 71,000Source | 71,000Source | — | — |
| Investment Income, InterestUSD | 1,012,000Source | 1,261,000Source | 615,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -26,555,000Source | -36,729,000Source | -30,544,000Source | -18,058,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -26,555,000Source | -37,824,000Source | -31,411,000Source | -18,058,000Source |
| Nonoperating Income (Expense)USD | 2,962,000Source | -4,612,000Source | — | -6,000Source |
| Operating ExpensesUSD | 29,517,000Source | 32,117,000Source | 21,449,000Source | 19,003,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -9,770,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 675,000Source | 951,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | 383,000Source |
| Operating Income (Loss)USD | -29,517,000Source | -32,117,000Source | -20,774,000Source | -18,052,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -9,770,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -26,555,000Source | -36,729,000Source | -30,544,000Source | -18,058,000Source |
| Earnings Per Share, BasicUSD per share | -1.67Source | -0.56Source | -1.28Source | -1.2Source |
| Earnings Per Share, DilutedUSD per share | -1.67Source | -0.56Source | -1.28Source | -1.2Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 15,886,876Source | 66,985,129Source | 24,539,309Source | 15,057,049Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 15,886,876Source | 66,985,129Source | 24,539,309Source | 15,057,049Source |
| Interest Expense (non-operating)USD | 71,000Source | 71,000Source | — | — |
| Additional Financial Items | ||||
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | 2,800,000Source | 2,800,000Source | 5,700,000Source | — |
| General and Administrative ExpenseUSD | 20,396,000Source | 12,103,000Source | 8,547,000Source | 6,567,000Source |
| Interest ExpenseUSD | — | — | 82,000Source | 6,000Source |
| Investment Income, InterestUSD | 1,012,000Source | 1,261,000Source | 615,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -26,555,000Source | -37,824,000Source | -31,411,000Source | -18,058,000Source |
| Nonoperating Income (Expense)USD | 2,962,000Source | -4,612,000Source | — | -6,000Source |
| Operating ExpensesUSD | 29,517,000Source | 32,117,000Source | 21,449,000Source | 19,003,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | 867,000Source | — |
| Research and Development ExpenseUSD | 9,121,000Source | 20,014,000Source | 12,902,000Source | 12,436,000Source |
Offerings
Registration 333-296545
Filing attachments
ea030696701ex99-1.htm · 8-K · 2026-09-29
Exhibit 99.1 Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate Resubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor The resubmission package includes 12 months of OLC drug product stability data from the new manufacturing vendor Company anticipates FDA acceptance of the NDA within 30 days of resubmission; new assigned PDUFA date expected to be 6 months from resubmission …
Read attachment ↗ea030169901ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 ea030169901ex99-1.htm PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED AUGUST 12, 2026 Exhibit 99.1 Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor - FDA has assigned a facility inspection to third-party manufacturing vendor of OLC - As of June 30, 2026, u…
Read attachment ↗ea029178901ex4-3.htm · S-3 · 2026-06-05
Exhibit 4.3 UNICYCIVE THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF, 20__ SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUT…
Read attachment ↗ea029178901ex4-4.htm · S-3 · 2026-06-05
Exhibit 4.4 UNICYCIVE THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF, 20__ SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXEC…
Read attachment ↗ea029027701ex99-1.htm · 8-K · 2026-05-12
EX-99.1 2 ea029027701ex99-1.htm PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MAY 12, 2026 Exhibit 99.1 Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 ─────────────────────────────────────────────────────────…
Read attachment ↗ea028394201ex99-1.htm · 8-K · 2026-03-30
EX-99.1 2 ea028394201ex99-1.htm PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MARCH 30, 2026 Exhibit 99.1 Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 ───────────────────────────────────────────────────────────────────────────…
Read attachment ↗